Share

September 2020; 7 (5) EditorialOpen Access

Isotyping paranodal antibodies in inflammatory neuropathies

One step closer to precision care

Cinta Lleixà, Luis Querol
First published July 24, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000843
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
399

Share

Article Information

vol. 7 no. 5 e843
DOI: 
https://doi.org/10.1212/NXI.0000000000000843
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published July 24, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work, provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Cinta Lleixà, BSc and
    2. Luis Querol, MD, PhD
  1. Cinta Lleixà, BSc and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Luis Querol, MD, PhD
    3. Scientific Advisory Boards:

    1. Commercial entity: Sanofi-Genzyme, CSL Bering, Grifols, Novartis, UCB Pharma, Johnson and Johnson, Alexion, Annexon

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial: CSL Behring, Novartis, Roche and Biogen, travel grant

    Editorial Boards:

    1. Editorial Board Member of the European Journal of Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Commercial: CSL Behring, Roche, Sanofi, Grifols, Merck, Novartis

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grifols

    Research Support, Government Entities:

    1. (1) Fondo de Investigaciones Sanitarias, PI19/01407 (2) SLT006/17/00131 of the Pla estratègic de Recerca i Innovació en Salut (PERIS), Departament de Salut, Generalitat de Catalunya (3) ACCI 2019-30 CIBERER

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. GBS-CIDP Foundation International

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuromuscular Diseases Unit (C.L., L.Q.), Neurology Department, Hospital de la Santa Creu I Sant Pau, Barcelona; and Centro para la Investigación Biomédica en Red en Enfermedades Raras (C.L., L.Q.), CIBERER, Madrid, Spain.
  1. Correspondence
    Dr. Querol lquerol{at}santpau.cat
View Full Text

Article usage

Article usage: July 2020 to August 2023

AbstractFullPdfSource
Jul 202009822Highwire
Aug 202016223Highwire
Sep 2020749660Highwire
Oct 202015411Highwire
Nov 202012915Highwire
Dec 202034711Highwire
Jan 20212337Highwire
Feb 202142210Highwire
Mar 20214448Highwire
Apr 202121912Highwire
May 20210131Highwire
Jun 20212198Highwire
Jul 202101011Highwire
Aug 2021171Highwire
Sep 20210118Highwire
Oct 202123026Highwire
Nov 202101215Highwire
Dec 20210406Highwire
Jan 20220172Highwire
Feb 20222164Highwire
Mar 20220447Highwire
Apr 2022095Highwire
May 202201211Highwire
Jun 20221158Highwire
Jul 20221117Highwire
Aug 20220227Highwire
Sep 20221309Highwire
Oct 202202111Highwire
Nov 202204215Highwire
Dec 20220137Highwire
Jan 20231246Highwire
Feb 20230347Highwire
Mar 20230106Highwire
Apr 2023045Highwire
May 20231146Highwire
Jun 20231105Highwire
Jul 202301310Highwire
Aug 2023086Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles